CompletedPhase 3

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Canada210 participantsStarted 2018-04-01

Plain-language summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with STEMI undergoing primary PCI and,
✓. ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
✓. Randomization within 6 to 12 hours of symptom onset and,
✓. Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.

Exclusion criteria

✕. Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
✕. Any other absolute or relative contraindication to fibrinolytic therapy.
✕. Administration of a fibrinolytic ≤24hrs prior to randomization.
✕. Cardiogenic shock on presentation.
✕. Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study).
✕. Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
✕. Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.

What they're measuring

MACE OR Myocardial Blush Grade 0/1 OR Distal Embolization OR Failure to Achieve ≥50% ST-segment Resolution

Timeframe: 30 days post-randomization

Trial details

NCT IDNCT03335839

SponsorPopulation Health Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-17

View on ClinicalTrials.gov More Myocardial Infarction trials